论文部分内容阅读
Ｃｈｏｌａｚｏｌ于１９９４年进入Ⅰ期临床试验Ｃｈｏｌａｚｏｌ是Ａｌｐｈａ－Ｂｅｔａ公司第二个产品，它是一种非全身性降胆固醇药。分析家们认为每年降胆固醇药约有２亿美元，与其他降胆固醇药相比，Ｃｈｏｌａｚｏｌ作用更佳，它将在１９９４年期进入Ⅰ期临床试验。...
Cholazol Enter Phase I Clinical Trial in 1994 Cholazol is Alpha-Beta’s second product, a non-systemic cholesterol-lowering drug. Analysts think about $ 200 million in cholesterol-lowering drugs each year and Cholazol works better than other cholesterol-lowering drugs and will enter Phase I clinical trials in 1994. ...